ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $18.83 Average Target Price from Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been given an average rating of “Moderate Buy” by the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $18.83.

ALXO has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research note on Friday, April 12th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of ALX Oncology in a research report on Wednesday, April 10th. Finally, Stifel Nicolaus restated a “hold” rating and set a $14.00 price objective (up from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $15.60 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.24 and a quick ratio of 5.24. The business has a 50-day moving average of $13.59 and a 200-day moving average of $11.97. The stock has a market capitalization of $780 million, a price-to-earnings ratio of -4.16 and a beta of 1.58. ALX Oncology has a fifty-two week low of $3.94 and a fifty-two week high of $17.42.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). As a group, sell-side analysts predict that ALX Oncology will post -3.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Jaume Pons sold 20,000 shares of ALX Oncology stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the sale, the insider now owns 628,359 shares of the company’s stock, valued at approximately $7,006,202.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Jason Lettmann acquired 4,400 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were purchased at an average cost of $11.31 per share, with a total value of $49,764.00. Following the acquisition, the chief executive officer now directly owns 171,620 shares in the company, valued at approximately $1,941,022.20. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jaume Pons sold 20,000 shares of the stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total value of $223,000.00. Following the transaction, the insider now owns 628,359 shares in the company, valued at approximately $7,006,202.85. The disclosure for this sale can be found here. Company insiders own 50.30% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

Institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in ALX Oncology in the 4th quarter worth about $28,000. Royal Bank of Canada raised its position in shares of ALX Oncology by 226.6% in the second quarter. Royal Bank of Canada now owns 4,001 shares of the company’s stock valued at $30,000 after buying an additional 2,776 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of ALX Oncology by 42.6% in the fourth quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after buying an additional 684 shares during the period. UBS Group AG grew its position in ALX Oncology by 38.7% during the first quarter. UBS Group AG now owns 10,043 shares of the company’s stock worth $45,000 after buying an additional 2,801 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in ALX Oncology during the 3rd quarter worth $48,000. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.